Prognostication in Young and Old Patients with Waldenstrom's Macroglobulinemia: Importance of the International Prognostic Scoring System and of Serum Lactate Dehydrogenase

被引：17

作者：

Kastritis, Efstathios ^{[1
]}

Zervas, Konstantinos ^{[1
]}

Repoussis, Panagiotis ^{[1
]}

Michali, Evridiki ^{[1
]}

Katodrytou, Eirini ^{[1
]}

Zomas, Athanasios ^{[1
]}

Simeonidis, Argiris ^{[1
]}

Terpos, Evangelos ^{[1
]}

Delimbassi, Sossana ^{[1
]}

Vassou, Amalia ^{[1
]}

Gika, Dimitra ^{[1
]}

Dimopoulos, Meletios A. ^{[1
]}

机构：

[1] Univ Athens, Sch Med, Dept Clin Therapeut, Athens 11528, Greece

来源：

CLINICAL LYMPHOMA & MYELOMA | 2009年 / 9卷 / 01期

关键词：

Age; Anemia; Disease-specific survival; Hyperviscosity; SURVIVAL; LYMPHOMA; MODEL;

D O I：

10.3816/CLM.2009.n.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We analyzed 232 patients with previously untreated, symptomatic WM, of whom 10% were <= 50 years of age and 21% were > 75 years of age. Disease features and response to treatment were similar among age groups. Patients > 75 years of age had significantly shorter survival (OS; 53 months vs. 113 months for those > 50-75 years vs. not reached for patents <= 50 years of age; P < .001). Despite the fact that 33% of elderly patients died of causes unrelated to WM, disease-specific survival (DSS) was 72 months for patients > 75 years, 120 months for those > 50-75 years and not reached for patients <= 50 years (P = .001). International Prognostic Scoring System for WM (IPSSWM) could discriminate 3 risk groups with significantly different OS or DSS. The addition of elevated serum lactate dehydrogenase in the IPSS improved the ability of IPSS to identify a group of patents with a significantly worse outcome (median survival, 55 months).

引用

页码：50 / 52

页数：3

共 12 条

[1] Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: An update of a US intergroup trial (SW0G S9003) [J].

Dhodapkar, MV ;

Jacobson, JL ;

Gertz, MA ;

Crowley, JJ ;

Barlogie, B .

SEMINARS IN ONCOLOGY, 2003, 30 (02) :220-225

[2] Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia [J].

Dimopoulos, MA ;

Hamilos, G ;

Zervas, K ;

Symeonidis, A ;

Kouvatseas, G ;

Roussou, P ;

Gika, D ;

Karmiris, T ;

Bourantas, K ;

Zomas, A ;

Mitsouli, C ;

Xilouri, I ;

Vervessou, E ;

Matsis, K ;

Anagnostopoulos, N ;

Economopoulos, T .

ANNALS OF ONCOLOGY, 2003, 14 (08) :1299-1305

[3] HIGH SERUM LACTATE-DEHYDROGENASE LEVEL AS A MARKER FOR DRUG-RESISTANCE AND SHORT SURVIVAL IN MULTIPLE-MYELOMA [J].

DIMOPOULOS, MA ;

BARLOGIE, B ;

SMITH, TL ;

ALEXANIAN, R .

ANNALS OF INTERNAL MEDICINE, 1991, 115 (12) :931-935

[4] Waldenstrom macroglobulinaemia:: presenting features and outcome in a series with 217 cases [J].

García-Sanz, R ;

Montoto, S ;

Torrequebrada, A ;

de Coca, AG ;

Petit, J ;

Sureda, A ;

Rodríguez-García, JA ;

Massó, P ;

Pérez-Aliaga, A ;

Monteagudo, MD ;

Navarro, I ;

Moreno, G ;

Toledo, C ;

Alonso, A ;

Besses, C ;

Besalduch, J ;

Jarque, I ;

Salama, P ;

Rivas, JAH ;

Navarro, B ;

Bladé, J ;

Miguel, JFS .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (03) :575-582

[5] Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia [J].

Ghobrial, IM ;

Fonseca, R ;

Gertz, MA ;

Plevak, MF ;

Larson, DR ;

Therneau, TM ;

Wolf, RC ;

Hoffmann, RJ ;

Lust, JA ;

Witzig, TE ;

Lacy, MQ ;

Dispenzieri, A ;

Rajkumar, SV ;

Zeldenrust, SR ;

Greipp, PR ;

Kyle, RA .

BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 (02) :158-164

[6] STUDY OF PROGNOSIS IN WALDENSTROMS MACROGLOBULINEMIA - A PROPOSAL FOR A SIMPLE BINARY CLASSIFICATION WITH CLINICAL AND INVESTIGATIONAL UTILITY [J].

GOBBI, PG ;

BETTINI, R ;

MONTECUCCO, C ;

CAVANNA, L ;

MORANDI, S ;

PIERESCA, C ;

MERLINI, G ;

BERTOLONI, D ;

GRIGNANI, G ;

POZZETTI, U ;

CAPORALI, R ;

ASCARI, E .

BLOOD, 1994, 83 (10) :2939-2945

[7] Prognostic factors in symptomatic Waldenstrom's macroglobulinemia [J].

Merlini, G ;

Baldini, L ;

Broglia, C ;

Comelli, M ;

Goldaniga, M ;

Palladini, G ;

Deliliers, GL ;

Gobbi, PG .

SEMINARS IN ONCOLOGY, 2003, 30 (02) :211-215

[8]

Morel P, 2000, BLOOD, V96, P852

[9]

Morel P, 2006, BLOOD, V108, p42A

[10] Waldenstrom macroglobulinemia - Development of diagnostic criteria and identification of prognostic factors [J].

Owen, RG ;

Barrans, SL ;

Richards, SJ ;

O'Connor, SJM ;

Child, JA ;

Parapia, LA ;

Morgan, GJ ;

Jack, AS .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2001, 116 (03) :420-428

← 1 2 →